Mitigating Risks from Human Xylazine Exposure: A Public Meeting

Marriott Marquis
901 Massachusetts Ave, NW
October 4, 2023
9:15 AM-4:15 PM ET

Speaker Biographies

Jane B. Acri, PhD
Acting Deputy Director of the Division of Therapeutics and Medical Consequences (DTMC)
National Institute on Drug Abuse, National Institutes of Health

Dr. Jane Acri is the Acting Deputy Director of the Division of Therapeutics and Medical Consequences (DTMC) at the National Institute on Drug Abuse, National Institutes of Health. The Division manages a comprehensive portfolio of product development projects aimed at the treatment of substance use disorders as well as projects aimed at understanding the medical consequences of exposure to abused substances. The drug development portfolio includes over 20 active INDs spanning a range of new therapeutics as well as medical devices and neuromodulation methodologies. Prior to serving as Deputy, Dr. Acri was Chief of the Medication Discovery and Toxicology Branch within DTMC which supports the medication program through a contract portfolio of preclinical research contained within the Addiction Treatment Discovery Program. The Branch also administers a Toxicology Program focused largely on the conduct of preclinical safety pharmacology protocols to ensure that toxic effects of drugs of abuse (respiratory depression, hypertension, QT prolongation) will not be potentiated by pharmacological effects of new medications in development. This partially fulfills an FDA requirement to establish the safety of new medications to be tested in substance-using populations who may use drugs of abuse during treatment.

Alice Bell, LCSW
Overdose Prevention Project Coordinator
Prevention Point Pittsburgh

Alice Bell is the Overdose Prevention Project Coordinator for Prevention Point Pittsburgh. She has distributed naloxone at PPP's syringe service sites since 2005 and coordinates PPP's naloxone distribution and data collection. She provides training on Harm Reduction Strategies to Reduce Overdose and is an advocate for drug policy reform and working to promote harm reduction practices at the local, state, and national level. She is co-facilitator for the Opiate Safety with Naloxone Network.

Keith K. Burkhart, MD
Senior Advisor for Medical Toxicology, Division of Applied Regulatory Science
Office of Clinical Pharmacology, Office of Translational Sciences
Center for Drug Evaluation and Research, Food and Drug Administration (FDA)

Dr. Keith Burkhart is the Senior Advisor for Medical Toxicology in the Office of Translational Sciences, Office of Clinical Pharmacology, Division of Applied Regulatory Science. He received his medical toxicology training at Rocky Mountain Poison and Drug Safety in Denver and his emergency medicine training at the University of Cincinnati. His medical training was at the Medical College of Pennsylvania. Academically, he was a Professor of Emergency Medicine, Pharmacology, and Internal Medicine at the Pennsylvania State University College of Medicine.

Dr. Burkhart was the Medical Director of the Penn State Poison Center that included an inpatient critical care toxicology admitting service. He is a Past-President and Fellow of the American College of Medical Toxicology. He is a co-editor of Critical Care Toxicology. At the FDA, he uses informatics tools to evaluate the biological plausibility of safety signals and provides targeted advice for improving management of drug overdose.

Malik Burnett, MD, MBA, MPH
Assistant Professor, Center for Addiction Medicine, University of Maryland Midtown Campus
Medical Director, Center for Harm Reduction Services, Maryland Department of Health

As a physician, entrepreneur, and drug policy expert, Dr. Malik Burnett works to advance the broader drug policy reform agenda with the goal of shifting US drug policy from a framework based on criminal justice to one based on public health. Dr. Burnett currently serves as the Medical Director for the Maryland Department of Health's Center for Harm Reduction Services, an Assistant Professor in Addiction Medicine at the University of Maryland Midtown Campus, a consultant for the Maryland Addiction Consultation Service and as medical director of several community opioid treatment programs. Additionally, he serves as the Vice Chair of the American Society of Addiction Medicine Public Policy Committee. He attended Duke University where he completed undergraduate, medical, and business training. He earned his master's degree in Public Health from Johns Hopkins Bloomberg School of Public Health and completed his residency training in general preventive medicine at Johns Hopkins Hospital and his addiction medicine fellowship at the University of Maryland Medical Center.

Nabarun Dasgupta, PhD
Co-founder and Board Chair, REMEDY Alliance for the People
Senior Scientist, Injury Prevention Research Center, University of North Carolina-Chapel Hill

Dr. Nabarun Dasgupta tells true stories about health, with numbers. He is a senior epidemiologist and Innovation Fellow at the University of North Carolina. He has a two-decade track record of reducing drug harms through applied science. He works closely with people who use drugs and patients with chronic pain, not just as collaborators, but in a team of equals. He is the former Board Chair of the National Harm Reduction Coalition, and has served as an advisor to the FDA, CDC, and the World Health Organization. His team's work can be found at OpioidData.org.

Zachary Dezman, MD, MS
Division of Anesthesia, Addiction, Medicine, and Pain Medicine, Office of Neuroscience
Office of New Drugs, Center for Drug Evaluation and Research, FDA

Dr. Zachary Dezman is a medical officer in the Division of Anesthesiology, Addiction Medicine, and Pain Medicine within the Center for Drug Evaluation and Research at the Food and Drug Administration. He is also a Clinical Associate Professor in the Departments of Emergency Medicine and Epidemiology and Public Health at the University of Maryland School of Medicine. Dr. Dezman championed making fentanyl testing standard within the University of Maryland Medical System, the first hospital system in the state to do so and provided testimony to the U.S. Senate relating to the burden of illicit fentanyl use on Marylanders. His work has been featured in the Washington Post, Baltimore Sun, and Forbes Magazine. Dr. Dezman is a practicing emergency physician in downtown Baltimore.

Amanda DiStefano
Intelligence Analyst II
Liberty Mid-Atlantic High-Intensity Drug Trafficking Area (HIDTA)

Amanda DiStefano graduated with a master's degree in Criminology from the University of Pennsylvania in 2020 and immediately began her role at Liberty Mid-Atlantic HIDTA. Ms. DiStefano has been an intelligence analyst for three years and is primarily responsible for conducting strategic analysis of crime and public health data to assess threats in the Greater Philadelphia Area. She uses this analysis on emerging drug and crime trends to provide insight for counter drug strategic planning. Additionally, Ms. DiStefano provides investigative support to law enforcement agencies as well as serves as a liaison among law enforcement and public health partners to promote collaboration and information-sharing.

Gonçalo Gamboa da Costa, PhD
Senior Science Advisor
Office of the Chief Scientist
National Center for Toxicology Research, FDA

Dr. Gonçalo Gamboa da Costa is a Senior Science Advisor to the Center Director at FDA's National Center for Toxicological Research (NCTR). He received a bachelor's degree in biology from the University of Lisbon, Portugal, followed by a master's in Technologic Organic Chemistry from the New University of Lisbon, and a doctoral degree in Organic Chemistry from the Technical University of Lisbon. Following a postdoctoral appointment at the Institute of Cancer Research, Sutton, UK, Dr. Gamboa da Costa became Director of the Laboratory of Mass Spectrometry and Nuclear Magnetic Resonance at NCTR. Dr. Gamboa da Costa has been the principal investigator for several toxicological studies sponsored by an Interagency Agreement between the National Institute of Environmental Health Sciences' Division of Translation Toxicology and FDA/NCTR. His area of expertise is the implementation of mass spectral-based analytical methodologies to elucidate mechanisms of toxicity. Dr. Gamboa da Costa also serves as the FDA Liaison Officer to the National Toxicology Program (NTP).

Traci Green, PhD, MSc
Professor and Director, Opioid Policy Research Collaborative
Brandeis University

Dr. Traci Green is an epidemiologist whose research focuses on drug use, opioid use disorder, and drug-related injury. She earned a master's degree in Epidemiology and Biostatistics from McGill University and a doctoral degree in Epidemiology from Yale University. She helped design the ASI-MV®, a real-time illicit and prescription drug misuse surveillance system developed by Inflexxion, Inc. Prior to joining the Heller School at Brandeis, she served as Deputy Director of the Boston Medical Center Injury Prevention Center and Associate Professor of Emergency Medicine and Community Health Sciences at the Boston University Schools of Medicine and Public Health. Dr. Green is an Adjunct Professor at the Warren Alpert School of Medicine at Brown University where she co-directs the Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose at Rhode Island Hospital. She serves as an advisor to the Rhode Island Governor on addiction and overdose and consults for the Center for Disease Control and Prevention and the High Intensity Drug Trafficking Areas on public health and public safety opportunities.

David Holtgrave, PhD
Assistant Director
White House Office of National Drug Control Policy

Dr. David Holtgrave serves as the Assistant Director for Translational Research in the White House Office of National Drug Control Policy, as well as the US Emerging and Continuing Threats Coordinator. Dr. Holtgrave previously served as the Dean of the University at Albany School of Public Health, where he also held the titles of State University of New York (SUNY) Distinguished Professor, SUNY Empire Innovations Professor, and tenured Professor of Health Policy, Management, and Behavior (he is currently on leave). In addition, Dr. Holtgrave is an Adjunct Professor at the Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior & Society. His three-decade career in public health has also included senior leadership positions at the US Centers for Disease Control and Prevention, and Emory University as well as serving as Vice-Chair of the Presidential Advisory Council on HIV/AIDS during President Obama's administration.

Van A. Jackson
Drug Intelligence Officer
Liberty Mid-Atlantic High-Intensity Drug Trafficking Area (HIDTA)

Van Jackson is a 27-year law enforcement veteran retired from the Pennsylvania State Police Bureau of Criminal Investigation Eastern Interdiction unit. Jackson was a member of this unit for 18 years and completed over 22 years with the Pennsylvania State Police. Jackson detailed as a task force officer to the Federal Bureau of Investigation and Homeland Security Investigation. He then was assigned to the Philadelphia/Camden HIDTA Hotel Interdiction Task Force in Philadelphia. Jackson has conducted investigations in an undercover capacity for the state police and the FBI. He served as an instructor for Pennsylvania Top Gun undercover school for the National Guard Northeast Counter-Drug Program and is also an instructor for the DEA El Paso Intelligence Center/Jetway school, instructing hotel/motel and freight interdiction. Jackson was enlisted in the US Air Force, assigned to the 24th security police squadron at Howard Air Force Base in the Republic of Panama

assisting Air Force Office of Special Investigations (OSI) in drug investigations of Columbian cartel trafficking in South America. Jackson is currently assigned as Drug Intelligence Officer for Pennsylvania at Liberty Mid-Atlantic HIDTA in Philadelphia.

Christopher M. Jones, PharmD, DrPH, MPH
Director, Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration

Captain Christopher M. Jones currently serves as Director of the Center for Substance Abuse Prevention (CSAP) at the Substance Abuse and Mental Health Services Administration (SAMHSA). Captain Jones brings a wealth of experience to SAMHSA having led substance use, mental health, and injury and violence prevention policy, program, and research activities for more than a decade. Prior to becoming Director of CSAP, he served as the Director of the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention. In this role, he provided scientific leadership and overall management of the Center, including driving the Center's strategic direction and advancing the Center's priorities of preventing drug overdose, suicide, and adverse childhood experiences. During his career, Captain Jones has served in a variety of leadership roles in the U.S. Department of Health and Human Services (HHS).

Jean Ko, PhD
Deputy Director of Scientific Programs
Division of Overdose Prevention
Centers for Disease Control and Prevention

CDR Jean Ko is the Deputy Director of Scientific Programs for the Division of Overdose Prevention at the Centers for Disease Control and Prevention (CDC). She is a Commander in the United States Public Health Service and has served on multiple public health and humanitarian emergencies. Prior to the Division of Overdose Prevention, she served as a technical lead and subject matter expert in maternal mental health and substance use for CDC's Division of Reproductive Health. She joined the CDC as an Epidemic Intelligence Service Officer after receiving her doctorate from the Johns Hopkins Bloomberg School of Public Health.

Laurie Konsella, MPA
Senior Public Health Advisor, Office of Regional Health Operations Region 8
Office of the Assistant Secretary for Health
U.S. Department of Health and Human Services

Laurie Konsella is the Senior Public Health Advisor for the U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Health (OASH), Office of Regional Health Operations (ORHO), Region 8 (ND, SD, WY, MT, CO, UT). In this role, Konsella strives to foster coordination and collaboration across federal departments and serves as an extension of OASH to ensure that HHS priorities are incorporated at the local, state, tribal, and national levels. Konsella's current portfolio includes leadership roles for the ORHO Harm Reduction workgroup, the Region 8 Substance Use Disorder Consultation team, Region 8 Federal Partners/

Prevention Collaborative and for Region 8 syndemic work. Konsella was recognized as the 2023 Rocky Mountain Eagle Customer Service of the Year awardee. She began her federal career as a Presidential Management Fellow and received her MPA from the University of North Dakota.

Alex J. Krotulski, PhD
Associate Director, Toxicology/Chemistry
Center for Forensic Science and Research and Education

Dr. Alex J. Krotulski serves as an Associate Director at the Center for Forensic Science and Research and Education (CFSRE), working in the areas of forensic toxicology and forensic chemistry and is the Program Manager for NPS Discovery, the CFSRE's drug early warning system and flagship program for the identification and characterization of new and emerging synthetic drugs. Dr. Krotulski is an analytical chemist by training and practices as a forensic toxicologist. Dr. Krotulski holds faculty appointment and serves as the Assistance Program Director for the Thomas Jefferson University Master of Science in Forensic Toxicology (MSFT) program and was recently appointed as an Associate Editor for the Journal of Analytical Toxicology. Dr. Krotulski received his PhD degree in Analytical Chemistry from Temple University in 2019 following receipt of his master's degree in Forensic Science from Arcadia University in 2015 and bachelor's degree in Chemistry from Loyola University New Orleans in 2013. To date, Dr. Krotulski has authored or co-authored more than 55 publications in the areas of forensic toxicology, clinical toxicology, and forensic chemistry.

Martin Lína Alcaraz
Peer Educator, Sanos Corporation



Martin Lína Alcaraz works as a Peer Educator at the Sanos Corporation in Caguas, Puerto Rico. The Sanos Corporation is a Primary Health Center that receives federal funds to work with vulnerable populations in the community. They work with the homeless, public housing, and people with substance use disorders. Within the services offered the center has a Buprenorphine Clinic to help people with Opioid use problems. In his role, Alcaraz is certified to offer support during the recovery process. He is also a certified Medication Assisted Treatment Counselor (MAT Puerto Rico and Florida Recovery Training Academy). Alcaraz is currently participating in a clinical study with the Transition Clinic Network (TCN). Alcaraz has been in recovery for 10 years after being treated with Buprenorphine, and he uses his past experiences to help others with the same problem he had.

Zoe McElligott, PhD
Associate Professor
Bowles Center for Alcohol Studies
University of North Carolina-Chapel Hill

Dr. Zoe McElligott is the Associate Professor of Psychiatry and Pharmacology at the Bowles Center for Alcohol Studies. Dr. McElligott received her bachelor's from New York University in Neural Science in 2023 and subsequently earned her doctoral degree in Neuroscience in the lab of Danny Winder at Vanderbilt University in 2009, studying noradrenergic modulation of glutamatergic signaling in the bed nucleus of the stria terminalis. Dr. McElligott then completed a post-doc with Mark Wightman at the University of North Carolina (UNC), learning in vivo and ex vivo fast-scan cyclic voltammetry and spent a year in Garret Stuber's lab at UNC learning optogenetic and behavioral techniques. The McElligott Lab officially launched in the fall of 2015 at the Bowles Center for Alcohol Studies and the Departments of Psychiatry and Pharmacology. The McElligott lab studies preclinical models of substance use disorders with a heavy focus on alcohol and opioid use disorders. The McElligott Lab's research is funded by the FDA, NIAAA, and NIDA.

Lewis S. Nelson, MD, MBA
Professor and Chair of the Department of Emergency Medicine
Chief of the Division of Medical Toxicology
Rutgers New Jersey Medical School

Dr. Lewis Nelson is Professor and Chair of the Department of Emergency Medicine and Chief of the Division of Medical Toxicology at Rutgers New Jersey Medical School in Newark, New Jersey. He is board certified in emergency medicine, medical toxicology, and addiction medicine. Dr. Nelson serves as a long-standing consultant to CDC, DHS, and FDA and works closely with several professional organizations addressing clinical management and health policy issues regarding opioids, alcohol, and cannabis.

Elizabeth Oliva, PhD
VA National Opioid Overdose Education and Naloxone Distribution (OEND) Coordinator
VA Office of Mental Health and Suicide Prevention
Veterans Health Administration

Dr. Elizabeth Oliva received her doctoral degree in Developmental Psychopathology and Clinical Science from the University of Minnesota, where her graduate work examining the etiology of substance use from adolescence to early adulthood was funded by a National Science Foundation Graduate Fellowship. She completed her pre-doctoral clinical psychology internship at UCSD/VA San Diego. Dr. Oliva is the VA National Opioid Overdose Education and Naloxone Distribution (OEND) Coordinator and conducts research on VA OEND implementation and post-overdose care. Additionally, she is a Senior Evaluator for the VA Program Evaluation and Resource Center (PERC; one of three VA Office of Mental Health and Suicide Prevention evaluation centers) and an Investigator at the VA Center for Innovation to Implementation at the VA Palo Alto Health Care System. Dr. Oliva helped develop and implement the VA Stratification Tool for Opioid Risk Mitigation (STORM) and is an Associate Editor for the Substance Use & Addiction Journal.

Luis Román Badenas, PsyD
Clinical Psychologist
Intercambios, Puerto Rico

Dr. Luis Román Badenas is a Clinical Psychologist who graduated from Carlos Albizu University in Puerto Rico. He was a member of the Board of Directors of CoC PR 503, which groups projects that serve the homeless in 54 municipalities of the Island. He is also a member of the Puerto Rican Harm Reduction Coalition where he participates in the promotion of changes in drug policies in Puerto Rico. He has conducted several investigations with confined populations at the Center for Socio-medical Research and Evaluation of the Medical Sciences Campus of the University of Puerto Rico. He has participated as an expert lecturer in problematic substance use within the Association of Psychologists of Puerto Rico. Until December 2020, he served as Assistant Professor at the University of Puerto Rico, Carolina Campus, offering courses related to substance use disorders. He served as director and psychologist of the Mental Health Clinic of the SANOS Corporation in Caguas. He currently works as a clinical psychologist at Intercambios, Puerto Rico, a harm reduction organization and as a consultant in areas related to substance use disorders for the doctoral program in Health Psychology at Ponce Health Science University.

Jeanmarie Perrone, MD, FACMT
Director, Center for Addiction Medicine and Policy
Perelman School of Medicine, University of Pennsylvania

Dr. Jeanmarie Perrone is a Professor in the Department of Emergency Medicine and the founding Director of the Penn Center for Addiction Medicine and Policy at the University of Pennsylvania.

Dr. Perrone leads a program for the treatment of Opioid Use Disorder in the emergency department (ED) and a virtual telehealth bridge clinic (CareConnect) for low barrier access to medications for opioid use disorder. She has advocated at the state and national level for enhancing equitable care for substance use. She has attended numerous FDA meetings while serving on the Drug Safety and Risk Management Advisory Committee and is a lead Co-Investigator on a NIDA CTN multi-site study of ED initiated buprenorphine. She has won numerous awards for education and mentorship and is board certified in emergency medicine, medical toxicology, and addiction medicine.

Erin Russell, MPH
Principal
Health Management Associates

Erin Russell is a nationally recognized harm reduction expert employed as a Principal Consultant with Health Management Associates (HMA). Prior to joining HMA, Russell served with the Maryland Department of Health, where she led the creation of the state's harm reduction program portfolio. She spearheaded the establishment of Maryland's centralized naloxone access program, advocated for the legalization of syringe service programs and drug checking technologies, and created a sustainable funding pipeline for implementation and evaluation. Under her leadership, the Center for Harm Reduction Services doubled in size from 2019 to 2023 and increased

the reach of harm reduction efforts across the entire state. Russell has a master's degree in Public Health and a bachelor's degree in Sociology from the University of Pittsburgh. Currently, she is pursuing a doctoral degree in Public Health at the Johns Hopkins Bloomberg School of Public Health and is a Bloomberg American Health Initiative Fellow.

Timothy Stenzel, MD, PhD
Director, Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health, FDA

Dr. Timothy Stenzel directs the FDA's Office of In Vitro Diagnostics (OHT7) and has an extensive background, spanning more than 25 years, in executive leadership, innovation, companion diagnostics, research and development, FDA regulations, and clinical laboratory operations. He received his medical and doctoral degrees in Microbiology and Immunology, focusing on the Molecular Biology of DNA Replication, from Duke University after graduating with Honors in Chemistry from Grinnell College. Following his residency at Duke University, Dr. Stenzel was recruited to create Duke's Clinical Molecular Diagnostics Laboratory and served as the Clinical Molecular Diagnostics and Medical Director, Cytogenetics. He also joined the faculty of the Duke University School of Medicine and served as an Assistant Professor of Pathology, where his research focused on cancer and genetics, as well as directed the Clinical Cytogenetic and Molecular Diagnostics Laboratories and taught in the School of Medicine. He is board certified in Molecular Genetic Pathology and Anatomic and Clinical Pathology. Prior to joining the FDA in 2018, Tim served as Chief Operating Officer (COO) at Invivoscribe, focusing on Companion Diagnostics and Next Generation Sequencing/Massively Parallel Sequencing in Oncology. Other experience includes serving as Chief Scientific Officer and founder of the Molecular Diagnostics franchise at Quidel, Chief Medical Officer and Vice President of Research and Development at Asuragen, and Senior Director for Medical, Regulatory and Clinical Affairs at Abbott Molecular. He served as a Board Director at the ACMG Foundation for Genetic and Genomic Medicine from 2008 to 2013. As the OHT7 Director, Dr. Stenzel advises FDA leadership on all regulatory (pre-market and post-market) for in vitro diagnostics product issues that have an impact on Center and Agency level decisions, policy development, nationwide program execution and short and long-range program goals and objectives as well as provide executive leadership and scientific direction to the OHT7 staff.

Marta Sokolowska, PhD
Deputy Center Director of Substance Use and Behavioral Health
Center for Drug Evaluation Research, FDA

Dr. Marta Sokolowska is the Deputy Center Director for Substance Use and Behavioral Health in FDA's Center for Drug Evaluation and Research (CDER). She serves as the center's executive-level leader responsible for advancing FDA's public health response to the non-medical use of substances with abuse potential. With expertise in science-based assessment and management of drug abuse risks, Dr. Sokolowska advises senior FDA officials on shaping scientific and policy interventions and executing strategies pertaining to the use of controlled substances and behavioral health programs.

Dr. Sokolowska joined CDER in 2018 as Associate Director for Controlled Substances in the Office of the Center Director. In 2020, she began leading the Controlled Substances Program (CSP), which comprises the Controlled Substance Staff (CSS) and the Controlled Substances Initiatives (CSI) group. CSS provides consultation throughout FDA on evaluation of abuse potential of drugs and advises on all matters related to domestic and international drug scheduling. The strategy group pursues activities and policies to identify, mitigate, and manage emerging issues with controlled substances to minimize risks associated with problematic use while enabling appropriate access to these products for medical use.

Dr. Sokolowska is a recognized expert in drug abuse liability and scheduling strategies. She has facilitated numerous initiatives to improve public health by advancing the science of assessing drug abuse liability. Prior to joining FDA, Dr. Sokolowska held senior clinical and medical leadership roles in the pharmaceutical industry. She earned her doctoral degree in psychology from McMaster University in Canada.

Jennifer Tuerke
Executive Director
Voices of Hope Maryland

Jennifer Tuerke is Executive Director of Voices of Hope, Inc. (VoH), a peer-run nonprofit Recovery Community Organization in Maryland that serves Cecil and Harford counties. VoH offers syringe services, community wound care, backpack street outreach, Recovery Community Centers and two recovery houses. Fifty-one (51) of their 54 employees are humans in recovery. Jennifer was an original founder of VoH in 2013. Between CY 2019 and CY 2020, the number of fentanyl-related deaths in Cecil County increased by 65% (from 49 to 81), high for a small rural/suburban population of 103,725. The increase in Cecil County significantly exceeds the increase statewide; there was a 22% increase in fentanyl-related deaths for all of Maryland. VoH participates in the Rapid Analysis of Drugs (RAD) program through the Maryland Department of Health. Of the 292 samples sent to the RAD program from VoH Cecil since Dec. 2021, only 51 samples (17.5%) did not include xylazine. VoH strives to reduce deaths from overdose, end suffering from addiction, and increase access to treatment and recovery support through community engagement. Through state and local partnerships, VoH provides xylazine testing strips and education about xylazine and basic first aid, along with linkages to health care including transportation assistance.

Rachel Wightman, MD
Associate Professor of Emergency Medicine and Epidemiology
Alpert Medical School, Brown University

Dr. Rachel Wightman is an Associate Professor of Emergency Medicine and Epidemiology at Alpert Medical School of Brown University. She is triple board-certified in medical toxicology, emergency medicine, and addiction medicine. She serves as the Director of Toxicology and Addiction Medicine for Brown Emergency Medicine and a Consultant Medical Director at the Rhode Island Department of Health.

Her research interests are emerging drug use patterns, evaluation of toxicology testing results, and medication management of opioid use disorder. She co-founded the Rhode Island Buprenorphine Hotline, a statewide telehealth low-threshold buprenorphine treatment access line in partnership with RIDOH and BHDDH funded by SAMSHA. Dr. Wightman is currently PI on a NIDA funded

R21 investigating cannabis hyperemesis (R21DA055023). She is MPI on a FORE Foundation funded study evaluating the local drug supply and a NIDA study evaluating optimal buprenorphine maintenance dose for MOUD in patients with fentanyl use (UG3DA056880).

Susan C. Winckler, RPh, Esq.
Chief Executive Officer
Reagan-Udall Foundation for the Food and Drug Administration

Susan C. Winckler, RPh, Esq., is CEO of the Reagan-Udall Foundation for the Food and Drug Administration. The Foundation is the non-profit organization created by Congress to advance the mission of the FDA.

Prior to accepting the Foundation post in May of 2020, Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, industry leaders, and consumers with a neutral forum to address domestic and global issues.

As FDA Chief of Staff from 2007-2009, Winckler managed the Commissioner's office; served as his/her senior staff adviser; analyzed policies; and represented FDA before myriad government and external stakeholders. She simultaneously led FDA's Offices of Legislation, External Relations, Public Affairs, and Executive Secretariat.

As APhA Vice President Policy/Communications and Staff Counsel, she served as the association's lead spokesperson and senior liaison to Congress, the executive branch, state associations, and allied groups. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her JD *magna cum laude* from Georgetown University Law Center. She is an APhA Fellow, an elected member and Chair of the United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025), a member of the Purgo Scientific, LLC board, and a member of the Virginia Commonwealth University School of Pharmacy National Advisory Council.